Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010126 · ClinicalTrials.gov registry record · Phase 2
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
NCT01010126: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01010126 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 252 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01010126, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
Study Summary
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of cancer by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.
Interventions
- BIOLOGICAL Bevacizumab
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2009-09-08 |
| Est. Completion | 2017-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01010126
The ClinicalTrials.gov registry entry for NCT01010126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01010126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01010126 about?
NCT01010126 is a clinical study titled "Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer". This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such ...
What is the current status of trial NCT01010126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2009-09-08. Estimated completion is 2017-03-13.
What interventions are being tested in trial NCT01010126?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01010126?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.